Human Molecular Genetics, 2001, Vol. 10, No. 21 2353-2361
© 2001 Oxford University Press
Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina
1Department of Molecular Genetics, Institute of Ophthalmology, University College London, Bath Street, London EC1V 9EL, UK and 2Molecular Immunology Unit, Institute of Child Health, University College London, Guilford Street, London WC1N 1EH, UK
Received May 22, 2001; Revised and Accepted July 24, 2001.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
The retinal degeneration slow (rds or Prph2Rd2/Rd2) mouse, a model of recessive retinitis pigmentosa, lacks a functional gene encoding peripherin 2. This membrane glycoprotein is required for the formation of photoreceptor outer segment discs. The striking feature of the rds mouse is the complete failure to develop outer segments. We have previously examined the short-term effect of gene replacement therapy using an adeno-associated (AAV) vector and demonstrated induction of outer segments and improvement of photoreceptor function. Here we have extended our analysis and have demonstrated that the potential for ultrastructural improvement is dependent upon the age at which animals are treated, but the effect of a single injection on photoreceptor ultrastructure may be long-term. However, there was no significant effect on photoreceptor cell loss, irrespective of the date of administration, despite the improvements in morphology and function. Our investigation excluded procedure-related damage, vector toxicity and immune responses as major factors which might counteract the benefits of photoreceptor restoration, but suggested that transgene over-expression is of significance. These findings suggest that successful gene therapy in patients with photoreceptor defects may ultimately depend upon intervention in early stages of disease and upon accurate control of transgene expression.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
Photoreceptor dystrophies are one of the commonest causes of inherited blindness in the Western world. They may result from a defect in any one of over 50 different genes, many of which are photoreceptor specific (1). The proteins encoded by these genes include many of the enzymes of the phototransduction cascade, regulatory proteins important for photoreceptor-specific gene expression, and structural proteins important for the integrity of the outer segment. Peripherin 2 (also known as peripherin/rds) is an integral membrane glycoprotein that forms a heterodimer with ROM1. This complex appears to be necessary for the stabilization of the membranous outer segment discs which are renewed constantly throughout life. Mutations in Prph2, the gene encoding peripherin 2, have been shown to result in a variety of retinal diseases, including autosomal dominant retinitis pigmentosa and macular dystrophy [OMIM 179605; retinal degeneration, slow (RDS)]. A common feature of these diseases is the loss of photoreceptors and this is also present in the retinal degeneration slow (rds or Prph2Rd2/Rd2) mouse, which is characterized by the absence of photoreceptor outer segments and limited phototransduction. The Prph2Rd2/Rd2 mouse is homozygous for a null mutation in Prph2, and completely fails to develop photoreceptor discs and outer segments. Consequently, the photoreceptor cell layer undergoes progressive apoptotic cell loss. As in other models of retinal degeneration, it is not understood why the gene defect leads to induction of apoptosis. In the Prph2Rd2/Rd2 this process begins at
2 weeks after birth with apoptotic activity peaking at postnatal day 18 (P18) (2,3). The outer nuclear layer (ONL) of the retina, which consists of photoreceptor nuclei, is reduced from 11 rows of cells at P10 to a single row by the time the animals reach 12 months of age (4). Mice which are heterozygous for the null mutation (Prph2+/Rd2) have outer segments which are much shorter than in wild-type mice and are disorganized with irregular whorls of membranes. The rate of photoreceptor loss is considerably slower than in Prph2Rd2/Rd2 animals—the ONL is only reduced to half its normal thickness by 18 months after birth (5). Functionally, electroretinograms (ERGs) of Prph2Rd2/Rd2 mice have greatly diminished a-wave and b-wave amplitudes, which decline to virtually undetectable levels by 2 months (6). The Prph2Rd2/Rd2 mouse is a very useful tool for assessing the efficacy of gene therapy protocols for retinal dystrophies. It is a well characterized model with a relatively slow degeneration that provides sufficient time for therapeutic intervention. Furthermore, the extent and quality of the therapeutic intervention can be simply but unambiguously assessed by ultrastructural analysis. Since there is little by way of photoreceptor function and therefore extremely limited ERG responses in untreated adult animals, functional improvements can also be easily quantified.
We have recently demonstrated the feasibility of gene replacement therapy in this model using an adeno-associated virus (AAV) based vector carrying a Prph2 cDNA and demonstrated the induction of outer segments. Furthermore, these newly formed structures incorporated rhodopsin which resulted in a significant improvement in ERG responses (7). Despite this obvious initial success, there are several important questions which have not yet been addressed and which may have important general implications for gene therapy trials in patients with retinal degenerations. (i) Is the ability to induce outer segments dependent on the age at which animals are treated? It is particularly important to determine whether therapy is effective in advanced degeneration.(ii) What is the duration of ultrastructural improvement after a single injection? Whereas long-term expression of reporter genes has been shown in wild-type animals, the duration of expression of functional genes has not yet been reported in models of degeneration. (iii) Does treatment slow the rate of degeneration? Whilst this is an extremely important question, it is not a simple task to address in a comprehensive manner. Many factors may potentially influence the rate of degeneration in treated animals. These include: the procedure itself and damage due to retinal detachment, which may be more severe in disease than in normal health, toxicity of the viral preparation, the age at which the therapy is administered, the transduction efficiency and the proportion of retina that is treated, and the kinetics and level of gene expression.
In this study we wished to address these three questions and investigate the effects of functional gene delivery in both early and late stages of the Prph2Rd2/Rd2 degeneration. In order to distinguish between the effects of transgene expression and the process of gene delivery, we investigated a number of factors which maybe important at different times after treatment. For instance, treatment-related damage (e.g. temporary detachment) is likely to occur soon after injection, whereas possible transgene overexpression may occur only after after several weeks with a sustained impact on photoreceptor physiology only after several months.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
Ultrastructural improvement is dependent upon the age at which Prph2Rd2/Rd2 mice are treated
Subretinal injection of Prph2Rd2/Rd2 mice at P10 with rAAV carrying a prph2 cDNA driven by a rhodopsin promoter (AAV.Rho.prph2) results in the induction of a relatively high proportion of fairly well organized outer segments (Fig. 1). Whilst the effects of treatment are reproducible, the number of outer segments and the quality of these structures appears to be dependent upon viral titre and individual viral preparations (data not shown). Therefore, we only used aliquots from one viral preparation for all subsequent experiments. In order to determine whether the ability to induce outer segments is dependent on the age at which animals are treated, mice were injected at P5, P10, P20, P40, P80 and P95 and killed 32 days later. There was a significant difference in the number and quality of outer segments, depending on the age at which the mice were treated, with more outer segments induced in the younger animals (Fig. 2A) which, in general, also had better assemblies of membranous stacks (Fig. 2B). However, even when adult mice (P95) in an advanced state of degeneration were treated, transduced photoreceptors still expressed the prph2 transgene and produced some well organized outer segments.
|
|
Duration of ultrastructural improvement in Prph2Rd2/Rd2 mice after a single injection is at least 9 months
In contrast to adenovirally mediated gene delivery in which there is a substantial immune response starting around day 2 after subretinal injection (8), AAV-mediated gene delivery into the subretinal space does not appear to elicit a significant immune response. There were no T or B cells detectable by immunohistochemistry in the detached area, and F4-80 immunostainings showed neither a significant increase in microglial activation in Prph2Rd2/Rd2 mice nor activation or migration to the subretinal space in wild-type mice (data not shown). Stable AAV-mediated GFP reporter gene expression was observed for at least 12 months in wild-type mice and for at least 8 months in Prph2Rd2/Rd2 mice following subretinal injection of AAV carrying a GFP reporter gene driven by a CMV promoter (AAV.CMV.GFP) (Fig. 3A and B). We also observed stable, but photoreceptor-specific, reporter gene expression in Prph2Rd2/Rd2 mice following injection of AAV carrying a GFP reporter gene driven by a rhodopsin promoter (AAV.rho.GFP) irrespective of the age at which animals were injected (Fig. 3C).
|
Following injection of AAV.rho.prph2 in P10 Prph2Rd2/Rd2 mice, photoreceptor outer segments were still observed up to 42 weeks later (Fig. 4A) although in far fewer numbers and, in general, with less well aligned membranous stacks than at earlier assessment periods after injection. Analysis of outer segment shapes by scanning electron microscopy (SEM) revealed that the newly induced outer segments are initially more elongate and become thicker and more wrinkled over time (Fig. 4B). However, it should be noted that in all assessments some nicely organized individual outer segments were observed.
|
Effect on photoreceptor cell loss in Prph2Rd2/Rd2 mice following treatment
Limited damage due to procedure. A reduction in the rate of photoreceptor cell loss following treatment is dependent upon any beneficial effects of gene replacement not being outweighed by damage due to the temporary retinal detachment caused by the procedure. In order to examine the effects of detachment in wild-type and Prph2Rd2/Rd2 mice, we injected animals with PBS and examined retinae 1, 3, 7, 14 and 21 days later for apoptotic photoreceptors using TUNEL, and rhodopsin redistribution, which is a commonly used indicator of photoreceptor distress (9). In wild-type animals, there was no obvious retinal damage, apoptotic cell death or cell stress in the detached areas apart from localized trauma around the injection site where there were some TUNEL-positive photoreceptors and focal rhodopsin redistribution (Fig. 5A and B). In Prph2Rd2/Rd2 mice, assessment is more difficult since the degeneration itself leads to rhodopsin redistribution and apoptosis. However, following subretinal injection of PBS there does not appear to be an increase in these features suggesting that the Prph2Rd2/Rd2 retina is not significantly more suceptible to damage than a healthy wild-type retina (data not shown).
|
Rationale for selection of time points for procedure. The time at which the vector is administered may be of significance for slowing the degeneration. In the Prph2Rd2/Rd2 mouse photoreceptor, apoptotsis begins around P16 (3), which is only 1 week after the normal onset of outer segment formation (P8–P10) in wild-type animals (10). Early treatment might be expected to offer the best chance of preventing photoreceptor apoptosis because some cells might express peripherin/rds at the appropriate physiological stage and the photoreceptors may be less compromised. On the other hand, with respect to potential clinical application, it is important to determine the effect on degeneration of injecting at advanced stages of degeneration. Therefore, we chose to procedure animals at early and late time points: P5, P10, P20, P40, P80 and P95.
Rationale for selection of time points for assessment. Since we are only transducing a minority of photoreceptors in treated Prph2Rd2/Rd2 retinae, assuming that only transduced cells are significantly protected from cell death, the maximal percentage difference in ONL thickness we might expect between treated and untreated animals at any given assessment time approximates to the percentage difference in ONL thickness between time of procedure and the time of assessment, multiplied by the proportion of transduced cells. We have previously estimated photoreceptor transduction rate following injection of rAAV by counting the number of fluorescent photoreceptor cells in cryosections from wild-type eyes which have been subretinally injected with AAV.CMV.GFP. We estimate that, at best, our transfection rate 2 weeks after injection is between 30 and 40% in the portion of the retina which has been detached. This also appears to be the case in the Prph2Rd2/Rd2 mouse in which 30% of the photoreceptors have induced outer segments 2 weeks after injection of AAV.rho.rds (Fig. 6A and B).
|
We observe in our untreated Prph2Rd2/Rd2 mice that
50% of the photoreceptor cells are lost between P10 and P42 and 15% are lost between P95 and P127. Although our results suggest a decreasing risk of photoreceptor cell death rather than a constant risk as found by Clarke et al. (11), both sets of data show that the rate of photoreceptor cell decline is largest before day 42. We transduce 30% of the photoreceptors in the area of detachment. If we treat at P10 and assess at P42, following the above assumptions, we might expect a 15% reduction in the loss of cells in the treated versus untreated areas provided that all transduced cells are protected. If there are additional neurotrophic benefits to untransduced photoreceptors we might observe an even better rescue. However, if we treat at P95 and assess at P127, we might only expect a 4.5% reduction in cell loss. Our method of assessing photoreceptor cell numbers is outlined in Figure 7. Using this method of assessment, a difference of 15% should be picked up quite easily at P42. However, if we treat at P95 and examine 40 days later, a 4.5% difference would be very difficult to ascertain.
|
There is no significant reduction in the loss of photoreceptors in the Prph2Rd2/Rd2 mouse following treatment
Subretinal injection of AAV.rho.rds was carried out in Prph2Rd2/Rd2 mice at either P5, P10, P20, P40, and the retinae analysed 32 days later. There was no statistically significant difference in ONL thickness between the transduced areas compared with site and age-matched controls (Fig. 8) even when mice were treated at P5 or P10. For long-term assessments, some animals were also analysed up to 43 weeks after injection and as with earlier time points there was no significant difference between treated and controls. In order to determine whether Prph2 overexpression may have harmful consequences, we treated wild-type animals with AAV.rho.rds and examined eyes up to 120 days later. We observed deleterious effects beginning around 8 weeks following injection of the rAAV carrying the Prph2 transgene with increasing photoreceptor cell loss over time. At 12 weeks following injection there was an extensive area of photoreceptor cell loss in all the injected eyes examined (Fig. 9A and B). We have never observed this type of damage following subretinal administration of AAV.CMV.GFP of similar titre.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
We have previously shown that AAV-mediated gene replacement therapy in young Prph2Rd2/Rd2 animals leads to induction of outer segments and improvement of photoreceptor function (7). In this study we have addressed two major issues: the effectiveness of treatment in older animals and whether it protects photoreceptors from cell death.
Although we are able to induce outer segments following the treatment of older animals, the number of outer segments and their quality is dependent upon the age at which the animals are treated. The reasons for this are not clear. If the physiology of the individual photoreceptor cell does not alter throughout the course of the degeneration until the final apoptotic programme is activated, we should expect due to higher vector concentration per cell, an even higher induction rate in older animals. It has been suggested that there might be a decline in the level of rhodopsin synthesis with advancing degeneration (12). Analysis of rhodopsin promoter activity following injection of AAV.rho.GFP in Prph2Rd2/Rd2 mice of different ages excluded the possibility of a drastic reduction in the effectiveness of the transgene promoter over time. Thus, alterations in photoreceptor cell physiology during the course of disease must be significant.
We observed a decline in ultrastructural quality of the outer segments over time even when we treated young animals. This might be explained either by increased disturbance of photoreceptor cell physiology over time, irrespective of outer segment induction, or by inappropriate transgene expression levels. We also observed that the number of induced outer segments decreased over time and that there was no reduction in the loss of photoreceptor cells following therapy. There are a number of possible explanations. We consider the major factors to be delayed onset or inappropriate levels of transgene expression or an insufficient transduction rate. A combination of all three and/or other factors may be important.
Delayed onset of transgene expression
Due to the delay in transcriptional activation of the rAAV genome (13), the earliest time at which we achieved substantial expression of Prph2 is P19, following injection at P5. At this stage the course of degeneration is well under way with apoptosis peaking at P18 (3). Therefore, it might be impossible to prevent further apoptosis only by introducing functional copies of the defective gene. The microenvironment of the degenerating retina itself might be deleterious due to soluble factors secreted by dying photoreceptor cells and activated microglia. This hypothesis is supported by studies of rhodopsin-transgenic/wild-type chimeric mice, in which genetically normal photoreceptor cells degenerate in the presence of mutant photoreceptors (14). Thus, a combined anti-apoptotic and gene replacement approach may be required.
Inappropriate expression of the transgene
It is difficult to estimate the level of transgene expression in transduced photoreceptor cells. Given the relative abundance of rhodopsin and peripherin transcripts in wild-type mice, the activity of the photoreceptor-specific rhodopsin promoter used to drive transgene expression is likely to be considerably higher than the endogenous peripherin promoter. However, this does not take into consideration the potential effects on transcriptional activity by the vector inverted terminal repeats (ITRs). In addition, there are probably multiple copies of the transgene in many of the transduced photoreceptor cells, with variation in copy number depending on proximity to injection site. Therefore, we are not likely to obtain homogenous levels of expression throughout retina. The fact that we do find individual photoreceptors with nicely organized outer segments at all stages throughout our study and even 9 months after treatment, provides an indication that at least some of the transfected cells are expressing the transgene at an appropriate level. However, in some instances we observe whorl-like structures which might indicate underexpression and more commonly very tightly packed discs suggesting overexpression. In order to determine whether administration of this rAAV vector might result in overexpression of the transgene and therefore be harmful to photoreceptor cells, we treated wild-type mice with AAV.rho.rds. We observed considerable loss of photoreceptor cells over time in these animals and therefore cannot exclude the possibility that the levels of transgene expression in treated Prph2Rd2/Rd2 mice eventually exceeds optimal levels. Ultimately it may be necessary to use a photoreceptor-specific inducible promoter system to cap the level of transgene expression and experiments are underway to determine whether such systems improve the rescue.
Photoreceptor transduction rate
In this study the typical area of detachment following subretinal injection covered 30% of the retina. Since the transduction efficiency in the area of detachment is 30% after 30 days, the transduction rate in the entire retina is only 10%. Previous studies involving the analysis of mutant rhodopsin transgenic/wild-type mouse aggregation chimeras, indicate that genetically normal photoreceptors degenerate in the presence of abnormal cells, suggesting that there is a complex interaction between healthy and unhealthy cells, possibly involving secreted neurotrophic factors. The rate of degeneration in these animals depended upon the proportion of abnormal cells in the retina, but even when 50% of the retina was composed of normal photoreceptors, these cells were still lost (14). Therefore, it is possible that we have not transduced a sufficient proportion of the retina to significantly alter the course of degeneration. We are now investigating whether we are able to improve the rescue by performing multiple injections in order to increase the proportion of transduced cells.
Prospects for clinical trials
The Prph2Rd2/Rd2 mouse provides a powerful tool for assessing the efficacy of gene therapy protocols for recessive retinal dystrophies. A truly effective treatment for this model should encompass restoration of photoreceptor structure, function and viability. Whilst it has been possible to improve photoreceptor structure and function following gene transfer, there was no significant reduction in the loss of photoreceptor cells following partial transduction of the retina. However, there was minor procedure-related damage which was confined to the injection site. The dytrophic retina does not appear to be significantly more fragile than healthy retina and, furthermore, induction of outer segments was possible even if therapy was applied in advanced stages of the degeneration. These findings are of clinical significance, since, in many cases, human retinal dystrophies are likely to be diagnosed at relatively advanced stages of disease. However, it is likely that following further refinement, the best prospects for therapy will result from early intervention.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
Plasmid constructions and production of rAAV
Three different rAAV vectors were used in this study. The vectors were prepared using a method we have described recently which utilizes replicating herpes simplex virus amplicons (containing the rAAV vector genome and the AAV helper genome on separate plasmids) and PS1 herpes simplex helper virus (15). The amplicon containing the vector genome (pHAV5) for the production of rAAV carrying a GFP reporter gene driven by a CMV promoter (AAV.CMV.GFP), and the amplicon containing the vector genome (pHAVRDS1) for the production of rAAV carrying a Prph2 cDNA driven by a rhodopsin promoter (AAV.rho.prph2) have been reported previously (15). The amplicon containing the vector genome (pHAVRhoGFP) for the production of rAAV carrying a GFP cDNA driven by a rhodopsin promoter (AAV.rho.GFP) was generated by the ligation of a 2.2 kb fragment (KpnI–XbaI) of the bovine rhodopsin promoter from gBR200-lacF (kind gift from D.Zack) into LITMUS 28 (NE BioLabs) upstream of an SV40 polyadenylation signal. The GFP cDNA was inserted between the two elements and the resulting cassette was ligated into an amplicon plasmid. rAAV vector stocks were purified using sequential caesium chloride gradients and dialysis against HEPES buffered saline. They were then concentrated by ultrafiltration (Microcon 30). Particle titres were calculated by comparative dot blot of DNA prepared from purified viral stocks and defined plasmid controls and all preparations were adjusted to 1 x 1010 particles/ml. The purity of viral stocks was confirmed by electron microscopy and by the absence of plaque formation on CR-1 cells. Contaminating wild-type-like AAV was present in all the stocks at
0.01% as measured by dot blot hybridization of low molecular weight DNA prepared from DNase-treated purified stocks. Replication competent wild-type-like AAV was not detectable by replication centre assay.
Subretinal injections
Injections were performed as described previously (7). Briefly, surgery was performed under direct retinoscopy through an operating microscope. The tip of a 1.5 cm, 34-gauge hypodermic needle (Hamilton, Switzerland) was guided in between the coverslip and the rubber sleeve to the sclera of the mouse eye and then inserted tangentially through it causing a self-sealing wound tunnel. The needle tip was brought into focus between the retina and retinal pigment epithelium and 1–2 µl of viral suspension (1 x 1010 particles of rAAV/ml) was injected to produce a bullous retinal detachment covering 30–40% of the fundus.
Immunohistochemistry
In total, 12 adult CBA and five Prph2Rd2/Rd2 pups (P10) were subretinally injected with PBS and killed after 1, 3, 7 or 21 days. Uninjected fellow eyes served as untreated controls. For TUNEL and rhodopsin immunostaining, eyes were fixed in 4% neutral buffered formaldehyde and embedded in paraffin wax. We serially sectioned (5 µm) entire eyes from treated animals. In order to detect apoptotic photoreceptor cells we used a commercially available fluorescent TUNEL kit (Apoptosis Detection System G3250; Promega) and followed the manufacturer’s instructions. For rhodopsin localization, slides were incubated for 1 h in blocking buffer (3% BSA and 10% normal goat serum in TBS) with a monoclonal rhodopsin-specific antibody (1:500). After washing in TBS, slides were incubated with the secondary antibody, Alexa Fluor® 594 goat anti-mouse IgG (H+L) conjugate (1:150; Molecular Probes, Leiden, The Netherlands) for 45 min. For microglia and T-cell immunostaining, animals were perfused with PLP fixative (periodate lysine paraformaldehyde: 2% paraformaldehyde, 0.05% gluteraldehyde) and serially cryosectioned (25 µm sections). Immunostaining for CD8- and CD4-positive T cells was carried out as described previously (8). For microglia staining we used a rat anti-mouse F4-80 specific antibody (1:25; Serotec, Oxford, UK) with an Alexa Fluor® 488 goat anti-rat IgG (H+L) conjugate as the secondary (1:150; Molecular Probes). For each immunostaining, except for rhodopsin, propidium iodide (PI) was used as a nuclear counterstain after the last washing step. In the case of rhodopsin immunostaining, DAPI was used as the counterstain. Slides were then mounted in an aqueous mounting medium (Dako S3023). We captured images using a confocal microscope (Zeiss LSM 510) operating in mutli-tracking mode.
Assessment of photoreceptor cell loss and photoreceptor outer segment structure by semithin and ultrathin sectioning
In total 29 Prph2Rd2/Rd2 mice were subretinally injected with AAV.rho.rds: three at P5, four at P10, three at P20, three at P40, two at P80, four at P95 and killed 32 days later; for long-term assessment, a further 10 Prph2Rd2/Rd2 animals were treated at around P10 and killed 18, 24, 32 or 42 weeks later. In total, 25 untreated age-matched Prph2Rd2/Rd2 controls were also analysed. In order to assess the effects of Prph2 over-expression, 10 wild-type CBA animals were also injected with AAV.rho.rds and killed up to 26 weeks later. The thickness of the ONL and the quality of the outer segement structures in treated areas was assessed by semithin sectioning and transmission electron microscopy (TEM). Mice were killed by cervical dislocation and the treated eyes removed after the corneas had been marked with a stitch and cautery so that the correct sagital orientation could be identified following enucleation. They were immersion fixed in 3% glutaraldehyde and 1% paraformaldehyde buffered to pH 7.4 with 0.07 M sodium cacodylate–HCl. The untreated contralateral eyes were processed similarly and served as controls. After 12 h of fixation, the anterior part of the eye was removed. The posterior segments were then osmicated for 2 h with a 1% aqueous solution of osmium tetroxide and dehydrated through ascending alcohols (50–100%, 10 min per step). After three changes of 100% ethanol, specimens were passed through propylene oxide (2 x 20 min) and left overnight in a 50:50 mixture of propylene oxide and araldite. Following a single change to fresh araldite (5 h with rotation) the specimens were embedded and cured overnight at 60°C. The eyes were cut using a Leica ultracut S microtome fitted with the appropriate type of diamond knife for semithin and ultrathin sections. Ten semithin and six corresponding ultrathin sections were taken at 10 different levels through the whole horizontal extension of each eye that was processed. Semithin sections were captured with a digital camera on a light microscope. Following sequential contrasting with 1% uranyl acetate and lead citrate, ultrathin sections were viewed and photographed using a JEOL 1010 transmission electron microscope operating at 80 kV. Each ultrathin section was assessed for outer segment induction and matched to the appropriate semithin picture. For measurement purposes, the only sections used were sagitally oriented central sections through the optic nerve head (ONH) which contained outer segments, as determined by TEM. On each side of the ONH at three different points (400, 1000 and 1600 µm from the edge of the ONH) a high-power field of the ONL was captured with a digital camera and the area of ONL measured using Image-Pro Plus 4.1 (Media Cybernetics, MD). In order to determine the average thickness of the ONL, the area was divided by the length of the section (between 130 and 150 µm) following the contour of the outer limiting membrane (Fig. 7). Three to six different eyes per timepoint were then averaged and plotted against the untreated controls.
Assessment of photoreceptor shapes and transduction efficiency by SEM
Six Prph2Rd2/Rd2 mice were subretinally injected with AAV.rho.rds at P10, and killed either 2, 4 or 8 weeks later. Whole retinae were removed from enucleated eyes and then immersion fixed and osmicated as for TEM. Following three changes in 100% ethanol, the retinae were critical point dried, mounted on stubs (scleral side upwards) with DAG and sputter coated with gold. We examined the specimens using a JEOL 6100 SEM operating at 15 kV. Transduction efficiency was estimated by comparing the number of visible cilia in untreated areas with the number of induced outer segments in areas of treated retina of equivalent size.
|
ACKNOWLEDGEMENTS |
|---|
This work was supported by grants from the Wellcome Trust and the Foundation Fighting Blindness (USA).
|
FOOTNOTES |
|---|
+ To whom correspondence should be addressed. Tel: +44 20 7608 6817; Fax: +44 20 7608 6863; Email: r.ali@ucl.ac.uk
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
1 Gregory-Evans, K. and Bhattacharya, S.S. (1998) Genetic blindness: current concepts in the pathogenesis of human outer retinal dystophies. Trends Genet., 14, 103–108.[Web of Science][Medline]
2 Chang, G.-Q., Hao, Y. and Wong, F. (1993) Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron, 11, 595–605.[Web of Science][Medline]
3 Portera-Cailliau, C., Sung, C.H., Nathans, J. and Adler, R. (1994) Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc. Natl Acad. Sci. USA, 91, 974–978.
4 Sanyal, S. and Jansen, H. (1981) Absence of receptor outer segments in the retina of rds mutant mice. Neurosci. Lett., 21, 23–26.[Web of Science][Medline]
5 Hawkins, R.K., Jansen, H.G. and Sanyal, S. (1985) Development and degeneration of retina in rds mutant mice: photoreceptor abnormalities in the heterozygotes. Exp. Eye Res., 41, 701–720.[Web of Science][Medline]
6 Reuter, J.H. and Sanyal, S. (1984) Development and degeneration of retina in rds mutant mice: the electroretinogram. Neurosci. Lett., 48, 231–237.[Web of Science][Medline]
7 Ali, R.R., Sarra, G.M., Stephens, C., Alwis, M.D., Bainbridge, J.W., Munro, P.M., Fauser, S., Reichel, M.B., Kinnon, C., Hunt, D.M., Bhattacharya, S.S. and Thrasher, A.J. (2000) Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet., 25, 306–310.[Web of Science][Medline]
8 Reichel, M.B., Ali, R.R., Thrasher, A.J., Hunt, D.M., Bhattacharya, S.S. and Baker, D. (1998) Immune responses limit adenovirally-mediated gene expression in the adult mouse eye. Gene Ther., 5, 1038–1046.[Web of Science][Medline]
9 Lewis, G.P., Erickson, P.A., Anderson, D.H. and Fisher, S.K. (1991) Opsin distribution and protein incorporation in photoreceptors after experimental retinal detachment. Exp. Eye Res., 53, 629–640.[Web of Science][Medline]
10 Cepko, C.L., Austin, C.P., Yang, X., Alexiades, M. and Ezzeddine, D. (1996) Cell fate determination in the vertebrate retina. Proc. Natl Acad. Sci. USA, 93, 589–595.
11 Clarke, G., Collins, R.A., Leavitt, B.R., Andrews, D.F., Hayden, M.R., Lumsden, C.J. and McInnes, R.R. (2000) A one-hit model of cell death in inherited neuronal degenerations. Nature, 406, 195–199.[Medline]
12 Nir, I., Agrawal, N. and Papermaster, D.S. (1983) Opsin gene expression during early and late phases of retinal degeneration in rds mice. Exp. Eye Res., 51, 257–267.
13 Ali, R.R., Reichel, M.B., de Alwis, M., Kanuga, N., Kinnon, C., Levinsky, R.J., Hunt, D.M., Bhattacharya, S.S. and Thrasher, A.J. (1998) Adeno-associated virus gene transfer to mouse retina. Hum. Gene Ther., 9, 81–86.[Web of Science][Medline]
14 Huang, P.C., Gaitan, A.E., Hao, Y., Petters, R.M. and Wong, F. (1993) Cellular interactions implicated in the mechanism of photoreceptor degeneration in transgenic mice expressing a mutant rhodopsin gene. Proc. Natl Acad. Sci. USA, 90, 8484–8488.
15 Zhang, X., de Alwis, M., Hart, S.L., Fitzke, F.W., Inglis, S.C., Boursnell, M.E.G., Levinsky, R.J., Kinnon, C., Ali, R.R. and Thrasher, A.J. (1999) High titre recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H. Hum. Gene Ther., 10, 2527–2537.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Allocca, C. Mussolino, M. Garcia-Hoyos, D. Sanges, C. Iodice, M. Petrillo, L. H. Vandenberghe, J. M. Wilson, V. Marigo, E. M. Surace, et al. Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors J. Virol., October 15, 2007; 81(20): 11372 - 11380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Peeters, N. N. Sanders, K. Braeckmans, K. Boussery, J. Van de Voorde, S. C. De Smedt, and J. Demeester Vitreous: A Barrier to Nonviral Ocular Gene Therapy Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3553 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Anzai, S. Yoneya, P. L. Gehlbach, D. Imai, L. L. Wei, and K. Mori Laser Photocoagulation and, to a Lesser Extent, Photodynamic Therapy Target and Enhance Adenovirus Vector-Mediated Gene Transfer in the Rat Retina Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nour, X.-Q. Ding, H. Stricker, S. J. Fliesler, and M. I. Naash Modulating Expression of Peripherin/rds in Transgenic Mice: Critical Levels and the Effect of Overexpression Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2514 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nour, A. B. Quiambao, M. R. Al-Ubaidi, and M. I. Naash Absence of Functional and Structural Abnormalities Associated with Expression of EGFP in the Retina Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Michaelides, D M Hunt, and A T Moore The genetics of inherited macular dystrophies J. Med. Genet., September 1, 2003; 40(9): 641 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Hughes, F. C. Schlichtenbrede, C. C. Murphy, G.-M. Sarra, P. J. Luthert, R. R. Ali, and A. D. Dick Generation of Activated Sialoadhesin-Positive Microglia during Retinal Degeneration Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2229 - 2234. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||